---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-282412"
form_type: "8-K/A"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-09-24T23:59:59+00:00"
generated_at: "2026-06-29T01:30:42.435860+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Aadi Bioscience files historical audited financials of acquired private company showing $32.6M deficit

## Summary
- Old Aadi reported net loss of $3.5M for 2020, revenue of $14.6M (primarily $14M license revenue).
- Accumulated deficit of $32.6M as of Dec 31, 2020; cash and equivalents of $4.5M.
- Auditor's report includes substantial doubt about going concern due to recurring losses and negative cash flows.
- As of Dec 31, 2020, the company had $14.3M payable to related party Celgene and $9M convertible promissory notes.
- Merger with Aadi Bioscience, Inc. closed Aug 26, 2021; these are the acquired entity's historical financials.

## SEC filing metadata
- accession: 0001193125-21-282412
- form_type: 8-K/A
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521282412/0001193125-21-282412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521282412/d207285d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-282412
- JSON: https://secwatch.observer/filing/0001193125-21-282412.json
- Plain text: https://secwatch.observer/filing/0001193125-21-282412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.